The FirstTake Podcast – Deucravacitinib delivers as Big Pharma endures a tough Q1

FirstWord Pharma PLUS editors Michael Flanagan, Simon King and Becky Simon discuss new Phase III data for Bristol Myers Squibb’s first-in-class psoriasis treatment deucravacitinib, the impact of the COVID-19 pandemic on Big Pharma’s first quarter performance and this week’s FDA AdCom meeting on accelerated cancer drug approvals.

Listen here

 

 

 

To read more ViewPoints articles, click here.

Reference Articles